William Blair Investment Management LLC bought a new stake in argenex SE (NASDAQ:ARGX – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund bought 223,666 shares of the company’s stock, valued at approximately $188,071,000.
Several other large investors have also recently bought and sold shares of the company. Capital World Investors increased its stake in argenex by 0.4% in the third quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock valued at $1,445,113,000 after purchasing an additional 8,422 shares in the last quarter. M&T Bank Corp increased its stake in argenex by 20,977.7% in the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock valued at $654,772,000 after purchasing an additional 774,916 shares in the last quarter. Wellington Management Group LLP increased its stake in argenex by 80.1% in the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after purchasing an additional 324,653 shares in the last quarter. Bank of America Corp DE increased its stake in argenex by 1.9% in the third quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock valued at $252,525,000 after purchasing an additional 6,259 shares in the last quarter. Finally, Two Sigma Investments LP increased its stake in argenex by 570.3% in the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock valued at $216,961,000 after purchasing an additional 250,278 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.
Analyst Ratings Changes
Several equities research analysts have commented on the stock. Robert W. Baird upped their target price on shares of argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a research note on Friday, February 27th. Zacks Research raised shares of argenex from a “strong sell” rating to a “hold” rating in a research note on Friday, February 20th. Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a report on Monday, April 20th. HC Wainwright upped their price target on shares of argenex from $915.00 to $940.00 and gave the company a “buy” rating in a report on Friday, February 27th. Finally, Wells Fargo & Company upped their price target on shares of argenex from $1,247.00 to $1,260.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, argenex presently has an average rating of “Moderate Buy” and an average target price of $1,017.78.
argenex Stock Down 1.2%
argenex stock opened at $806.46 on Friday. The stock has a market capitalization of $49.90 billion, a PE ratio of 35.91, a price-to-earnings-growth ratio of 1.28 and a beta of 0.46. argenex SE has a twelve month low of $510.05 and a twelve month high of $934.62. The company has a 50 day moving average of $767.17 and a 200-day moving average of $815.87.
argenex (NASDAQ:ARGX – Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The company had revenue of $1.31 billion during the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. Equities analysts anticipate that argenex SE will post 25.27 EPS for the current fiscal year.
argenex Company Profile
argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.
The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.
Read More
- Five stocks we like better than argenex
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX – Free Report).
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
